~ Un-Common Sense In An Irrational World: We Challenge the Conventional WisdomTM ~
TRETHERA RECEIVES $1.8M NIH CROHN’S GRANT
Trethera has announced that the National Institutes of Health (NIH) has awarded a $1.8M grant to advance preclinical development of TRE-515 as a potential treatment for Crohn’s disease.
- TRE-515 is a once-daily oral therapy targeting deoxycytidine kinase (dCK), a novel metabolic vulnerability driving autoimmune disease.
- In preclinical studies, TRE-515 outperformed Johnson & Johnson’s Stelara, blocking IBD symptoms in mice by selectively limiting activated CD4 T-cell proliferation.
- NIH peer review comments described TRE-515 as the only dCK inhibitor in development, noting its favorable safety profile and innovative approach.
This award builds on prior NIH funding and Trethera’s recent presentation at the Crohn’s & Colitis Congress. With this continued support, we are accelerating TRE-515 in development to address the high unmet needs of Crohn’s patients.
Read full press release: $1.8M NIH Grant for TRE-515 Crohn’s Research | Trethera
👉 Trethera’s Seed Series 5A Round is Open Through Sept 30 — Connect with Investor Relations: Investor Relations Contact | Trethera